Hungarian pharmaceutical company Gedeon Richter and Estetra, a unit of Belgian peer Mithra, have said they signed a licence and supply agreement for the commercialisation of a new oral contraceptive.
The oral contraceptive contains 15 mg estetrol (E4), a unique native estrogen, and 3 mg drospirenone.
Under the terms of the agreement Richter will distribute Mithra’s product in Mexico, Chile, Colombia, Peru and Ecuador, with an option for other markets except for Brazil and Argentina. Richter will make an upfront payment to be followed by milestone payments contingent on the progress of the regulatory process of the product and on sales after the product launch.
Richter announced a partnership with Mithra in September 2018 to sell the oral contraceptive. Under that agreement, Richter will sell the drug in Europe, Russia and other CIS countries under a different brand name. Mithra sells the contraceptive under the Estelle brand. Oral contraceptives are Richter’s top-selling products.
hungarymatters.hu
pixabay
